On Tuesday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.44% to $33.73.
Pfizer Inc., declared enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery. The purpose of the study, named STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy), is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery.
Surgical Site Infections (SSIs) are a noteworthyand growing concern. SSIs caused by S. aureus account for about 20 percent of all SSIs in the U.S., and are associated with an estimated annual treatment cost of $12.3 billion in the U.S. Patients who suffer such infections due to antibiotic resistant (MRSA) or antibiotic sensitive (MSSA) S.aureus have worse clinical outcomes, counting raised mortality in comparison with non-infected patients.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of MetLife, Inc. (NYSE:MET), declined -0.45% to $55.66, during its last trading session.
MetLife, declared a third quarter 2015 common stock dividend of $0.375 per share. The dividend will be payable on September 11, 2015, to shareholders of record as of August 7, 2015.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.
Finally, Express Inc. (NYSE:EXPR), ended its last trade with 2.54% gain, and closed at $18.58.
Express, declared that Perry Pericleous, formerly Vice President, Finance has been promoted to Senior Vice President, Chief Financial Officer and Treasurer reporting to Matthew Moellering, Executive Vice President and Chief Operating Officer. Mr. Pericleous succeeds Paul Dascoli who has left the Company, effective recently.
David Kornberg, the Company’s President and Chief Executive Officer, stated: “Perry is a natural choice for the Chief Financial Officer position at Express given his deep knowledge of our business and financials, his strong leadership skills and proven track record of performance during his 15 year tenure at our Company. Perry’s business acumen and financial discipline will be highly valuable to us as we continue to execute our growth strategies and work to profitably grow our business in the near and long term. I also want to thank Paul for his many contributions since joining Express in the fall of 2011.”
Matthew Moellering, Executive Vice President and Chief Operating Officer, stated: “We are happy to be in the position to promote Perry to Chief Financial Officer and expect a seamless transition. In this new role, we look forward to leveraging Perry’s deep financial and operational skills and strong thought leadership in an even greater way. I also want to thank Paul for his service to Express over the past three and a half years.”
Express, Inc. operates as a specialty apparel and accessories retailer. It offers apparel and accessories for women and men between 20 and 30 years across various aspects of lifestyles, counting work, casual, jeanswear, and going-out occasions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
